Skip to content
drillr.ai
Sign up

BBIO

BridgeBio Pharma, Inc.

NASDAQ · Healthcare · Biotechnology · US

$73.80
+4.34%
Ask drillr

  • Oct 29, 2026, 22:11 UTC

    BridgeBio Pharma, Inc. reported a third-quarter loss of $0.42 per share, compared with a loss of $0.95 per share a year earlier.

    Source:

  • Oct 29, 2026, 20:01 UTC

    BridgeBio reported third-quarter 2026 total revenue of $353.2 million, including $253.2 million in U.S. Attruby net product revenue, and an operating loss of $11.6 million.

    Source:

  • Oct 22, 2026, 11:30 UTC

    BridgeBio Pharma, Inc. announced that it will release its third-quarter 2026 financial results and business update after the market closes on October 29, 2026, and host a conference call at 4:30 p.m. ET that day.

    Source:

  • Oct 6, 2026, 20:01 UTC

    BridgeBio Pharma announced that it will present one oral presentation, three rapid-fire oral presentations and six poster presentations on acoramidis at the HFSA Annual Scientific Meeting 2026.

    Source:

  • Oct 6, 2026, 11:30 UTC

    The FDA accepted for priority review BridgeBio's New Drug Application for oral infigratinib for children with achondroplasia, with a PDUFA target action date of February 4, 2027.

    Source:

  • Oct 2, 2026, 13:20 UTC

    SonoThera hired Adam Shaywitz as chief medical officer; he previously held the same role at BridgeBio.

    Source:

  • Sep 9, 2026, 14:30 UTC

    BridgeBio Pharma announced new exploratory results from its Phase 3 PROPEL 3 trial of oral Infigratinib in children with achondroplasia, showing benefits beyond growth, and plans a potential U.S. launch in mid-2027.

    Source:

  • Aug 31, 2026, 19:14 UTC

    President Donald J. Trump announced agreements with nine additional pharmaceutical manufacturers to lower drug prices for Americans in line with most-favored-nation pricing.

    Source:

  • Aug 28, 2026, 09:23 UTC

    AstraZeneca announced on Friday that its Phase 3 clinical trial for an experimental silencer drug in ATTR-CM patients failed to show additional benefit over existing stabilizer therapy, impacting its partnership with Ionis Pharmaceuticals and the broader market.

    Source:

  • Aug 26, 2026, 11:30 UTC

    BridgeBio announced that the first participant has been dosed in ASCEND-ATTR, a Phase 3b/4 study evaluating the long-term effects of acoramidis on disease regression in ATTR-CM.

    Source:

  • Aug 24, 2026, 11:30 UTC

    BridgeBio Pharma announced that new acoramidis data from open-label extension analyses in ATTR-CM will be presented at the ESC Congress 2026 in Munich, Germany, on August 28-31, 2026.

    Source:

  • Aug 14, 2026, 00:35 UTC

    KKR affiliate is selling BridgeBio Pharma shares at $78-$80 per share, as reported on August 13, 2026.

    Source:

  • Aug 13, 2026, 21:42 UTC

    BridgeBio Pharma announced the launch of a secondary public offering of 5,000,000 shares of its common stock by selling stockholder KKR Genetic Disorder L.P.; BridgeBio will not receive any proceeds.

    Source:

  • Jul 22, 2026, 11:30 UTC

    BridgeBio Pharma announced that the FDA accepted for filing its New Drug Application for encaleret for the treatment of autosomal dominant hypocalcemia type 1.

    Source:

  • Jul 1, 2026, 11:30 UTC

    BridgeBio Pharma raised $1 billion in preferred equity financing led by Sixth Street and with participation from HealthCare Royalty, a business of KKR, at an initial conversion price of approximately $138 per share.

    Source:

  • Jun 26, 2026, 00:00 UTC

    BridgeBio Pharma announced the departure of director Randal W. Scott and the election of directors James C. Momtazee, Frank P. McCormick, and Hannah A. Valantine, effective June 22, 2026.